# Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

> **NCT00993616** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 29 (actual)

## Conditions studied

- Brenner Tumor
- Fallopian Tube Cancer
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mixed Epithelial Carcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Ovarian Undifferentiated Adenocarcinoma
- Primary Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer

## Interventions

- **DRUG:** belinostat
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00993616
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-07
- **Final completion:** 2012-07-29
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00993616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00993616, "Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00993616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*